Qube Research & Technologies (QRT)
RIGL icon

Qube Research & Technologies (QRT)’s Rigel Pharmaceuticals RIGL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-343,897
Closed -$9.3M – 3969
2026
Q1 		$9.3M Buy
343,897
+55,628
+19% +$1.87M 0.01% 1319
2025
Q4 		$12.3M Sell
288,269
-72,697
-20% -$2.74M 0.01% 1209
2025
Q3 		$10.2M Buy
360,966
+189,542
+111% +$5.67M 0.01% 1313
2025
Q2 		$3.21M Buy
171,424
+16,807
+11% +$319K ﹤0.01% 1962
2025
Q1 		$2.78M Buy
154,617
+36,660
+31% +$744K ﹤0.01% 1826
2024
Q4 		$1.98M Buy
+117,957
New +$2.26M ﹤0.01% 1884
2024
Q3 		– Sell
-17,667
Closed -$145K – 3973
2024
Q2 		$145K Buy
17,667
+8,596
+95% +$90K ﹤0.01% 2518
2024
Q1 		$134K Buy
+9,071
New +$122K ﹤0.01% 3196
2023
Q4 		– Sell
-12,433
Closed -$134K – 4672
2023
Q3 		$134K Sell
12,433
-2,648
-18% -$31.9K ﹤0.01% 2560
2023
Q2 		$195K Sell
15,081
-32,256
-68% -$436K ﹤0.01% 1788
2023
Q1 		$625K Buy
+47,337
New +$752K ﹤0.01% 1478
2022
Q4 		– Sell
-57,661
Closed -$680K – 2909
2022
Q3 		$680K Buy
+57,661
New +$780K ﹤0.01% 1351
2022
Q2 		– Sell
-11,201
Closed -$335K – 3033
2022
Q1 		$335K Buy
11,201
+919
+9% +$24.9K ﹤0.01% 1726
2021
Q4 		$272K Sell
10,282
-863
-8% -$26K ﹤0.01% 1848
2021
Q3 		$405K Buy
11,145
+9,208
+475% +$362K 0.01% 1331
2021
Q2 		$84K Sell
1,937
-7,182
-79% -$271K ﹤0.01% 1972
2021
Q1 		$312K Buy
9,119
+4,975
+120% +$197K ﹤0.01% 1437
2020
Q4 		$145K Buy
+4,144
New +$120K ﹤0.01% 1591

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RIGL Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 343,897 shares — an estimated $9.3M sold.

Qube Research & Technologies (QRT) first reported a position in RIGL in Q4 2020 and held it in 18 quarters. The position peaked at $12.3M in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 343,897 Rigel Pharmaceuticals shares in Q2 2026, an estimated $9.3M.
  • Qube Research & Technologies (QRT) first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 18 quarters.
  • Qube Research & Technologies (QRT)'s Rigel Pharmaceuticals position peaked at $12.3M in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.